- Home
- VGI vs IFRX Comparison
VGI vs IFRX Comparison
Compare VGI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- IFRX
- Stock Information
- Founded
- VGI 2012
- IFRX 2007
- Country
- VGI United States
- IFRX Germany
- Employees
- VGI N/A
- IFRX N/A
- Industry
- VGI Investment Managers
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- VGI Finance
- IFRX Health Care
- Exchange
- VGI Nasdaq
- IFRX Nasdaq
- Market Cap
- VGI 85.1M
- IFRX 93.6M
- IPO Year
- VGI N/A
- IFRX 2017
- Fundamental
- Price
- VGI $7.94
- IFRX $1.52
- Analyst Decision
- VGI
- IFRX Strong Buy
- Analyst Count
- VGI 0
- IFRX 2
- Target Price
- VGI N/A
- IFRX $13.50
- AVG Volume (30 Days)
- VGI 46.0K
- IFRX 68.2K
- Earning Date
- VGI 01-01-0001
- IFRX 10-30-2024
- Dividend Yield
- VGI 12.66%
- IFRX N/A
- EPS Growth
- VGI N/A
- IFRX N/A
- EPS
- VGI N/A
- IFRX N/A
- Revenue
- VGI N/A
- IFRX $113,022.00
- Revenue This Year
- VGI N/A
- IFRX $311.47
- Revenue Next Year
- VGI N/A
- IFRX $227.11
- P/E Ratio
- VGI N/A
- IFRX N/A
- Revenue Growth
- VGI N/A
- IFRX N/A
- 52 Week Low
- VGI $6.68
- IFRX $1.14
- 52 Week High
- VGI $7.99
- IFRX $4.15
- Technical
- Relative Strength Index (RSI)
- VGI 68.86
- IFRX 49.53
- Support Level
- VGI $7.87
- IFRX $1.55
- Resistance Level
- VGI $8.03
- IFRX $1.69
- Average True Range (ATR)
- VGI 0.07
- IFRX 0.10
- MACD
- VGI 0.01
- IFRX 0.01
- Stochastic Oscillator
- VGI 72.73
- IFRX 51.43
About VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objectives by capitalizing on opportunities across undervalued areas of the global bond markets.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.